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Abstract 
Background Although serum thyrotropin (TSH) is often elevated in obesity and may be linked to 
disorders of lipid and glucose metabolism, the clinical relevance of these relationships remains 
unclear.  
Subjects Obese children and adolescents (n=206; mean age, 14 y) undergoing rapid weight and fat 
loss in a standardized, multidisciplinary, 2-month, in-patient weight loss program. 
Design A prospective study that determined thyroid function, glucose and lipid parameters, leptin, 
anthropometric measures and body composition measured by DEXA at baseline and at the end of the 	
intervention. 

Results At baseline, 52% of children had TSH concentrations in the high normal range (> 2.5 mU/l) 
but TSH was not correlated with body weight, BMI-SDS, lean body mass or body fat percentage. At 
baseline, independent of adiposity, TSH significantly correlated with total cholesterol (p=0.008), LDL-
cholesterol (p=0.013), fasting insulin (p=0.010), HOMA (p=0.004) and leptin (p=0.006). During the 
intervention, mean body fat, TSH, HOMA and fasting insulin decreased by 21%, 11%, 53% and 54%, 
respectively. Change in (∆)TSH did not correlate with ∆body weight or ∆body composition, but ∆TSH 
significantly correlated with, ∆fasting insulin and ∆HOMA, independent of ∆body weight or ∆body 
composition (p<0.05). 
 Conclusion TSH concentrations are elevated in obese children but are not correlated with the amount 	
of excess body weight or fat. During weight loss, independent of changes in body weight or 

composition, decreases in elevated serum TSH predict decreases in fasting insulin and HOMA. These 
findings suggest interventions that target high TSH concentrations during weight loss in obese subjects 
may improve insulin sensitivity. 
 

 
Introduction   
Higher serum thyrotripin (TSH) concentrations are consistently found in obese children and adults 
compared to normal weight individuals (1-4). But the cause of the higher TSH concentrations in 
obesity, and whether they are an independent risk factor for disease, remains unclear. Some authors 
have argued higher TSH is simply a metabolic adaptation to obesity (5). Others have suggested 
obesity-related subclinical hypothyroidism (ScH), characterized by an increased serum thyrotropin 
(TSH) concentration with normal concentrations of the thyroid hormones, may be associated with 
dyslipidemia, insulin resistance, subclinical inflammation and increased risk for coronary heart disease 	
(CHD) (6, 7). Even within the normal reference range for TSH, higher TSH has been linked to higher 

body mass index (BMI), dyslipidemia and fatal CHD (8-10). If an increased TSH in obesity is a risk 
factor, then thyroid hormone therapy in obese individuals with ScH to reduce TSH could be potentially 
beneficial, but this is controversial (5).  
One of the potential causes of higher TSH concentrations in obesity is leptin, the adipocyte derived 
hormone that is increased with increasing body fat.  In humans, direct correlations between TSH and 
leptin have been reported in cross-sectional and longitudinal studies (2). Leptin stimulates TSH 
production by the hypothalamic-pituitary axis in rats (11). At the same time, TSH may stimulate leptin 
production by adipocytes (12), suggesting cross-talk between these two hormones.  
To clarify these issues, more data from prospective studies on the relationships between changes in 	
thyroid function during weight loss, leptin, insulin resistance and other metabolic risk factors for CHD 

would be valuable. Such studies in obese children and adolescents may be particularly useful in that 
these relationships are less likely to be confounded by concurrent smoking, alcohol use, 
pharmacotherapy and/or chronic diseases. There is only one previous report in this age group; in obese 
German children in a 1 year outpatient program, weight loss significantly reduced TSH but changes in 
TSH were not associated with changes in lipids or insulin sensitivity (1). But only ≈20% of children 
successfully lost weight, and fat and lean tissue loss were not quantified.  
 
Therefore, the aim of this study was to prospectively examine the associations between changes in 
thyroid function, leptin, insulin resistance and other metabolic risk factors for CHD in obese children 
and adolescents undergoing rapid weight and fat loss in a well-controlled, multidisciplinary, eight 
week inpatient program. We hypothesized that a greater decrease in TSH during weight loss would 
predict a greater decrease in insulin, LDL-cholesterol and triglyceride concentrations, independent of 
changes in body weight or body composition. 
 
Subjects and methods 	
Subjects 

The subjects were obese children and adolescents (n=206) aged 10-18 y enrolled in a multidisciplinary 
in-patient weight-loss program at the Alpine Children’s Hospital in Davos, Switzerland. Inclusion 
criteria were a BMI over the 98th percentile for age and sex. Exclusion criteria were secondary obesity, 
(e.g. due to the Prader-Willi syndrome or underlying endocrine diseases; based on the medical history 
and/or clinical exam), type 2 diabetes and impaired glucose tolerance, or other major medical 
problems. The subjects were referred to the clinic by general pediatricians throughout Switzerland. 
Subjects and their parents or caregivers provided written informed consent. Ethical approval was 
obtained from the Canton of Graubünden Ethics Commission in Chur, Switzerland. Results on the 
effect of this program on body composition, aerobic fitness and quality of life in a subgroup and 	
gender-specific differences have previously been described (13).Power calculations indicated 200 

subjects should be studied to detect a TSH reduction of 10% (≈0.28 mU/l) considering a standard 
deviation of the TSH difference of 1.15 and with a power of 90% and a significance level of 0.05.  
Study design 
The treatment program consisted of moderate caloric restriction, daily physical activity and a behavior 
modification regimen (13). Baseline data were available for 206 subjects; 197 completed the 8-wk 
intervention. 
 
Nutritional intervention. A 3-d food record was done at the beginning of the program to estimate the 
quality and quantity of the subject’s usual diet. All children and adolescents received a nutritionally 
balanced diet, with the daily caloric intake during the program based on each patient’s weight at 
baseline: weight <50 kg: 1200 kcal; weight 50-80 kg: 1400 kcal; and weight >80 kg: 1600 kcal. Five 
regular meals were given each day. The macronutrient composition was based on the 
recommendations of the Swiss Nutrition Society (www.sge-ssn.ch) and provided 55 to 60% energy as 
carbohydrates, 25-30% as fat and 15-20% as protein. Non-caloric drinks such as water and 
unsweetened tea were unrestricted. Nutritional education was provided to the subjects in weekly 	
sessions: a 1-h group meeting, 30 min individual consultation and 2 h session with practical 

instructions in cooking and sensory aspects of food.  
Physical activity program. The compulsory physical activity program included two daily group 
endurance exercise sessions to improve aerobic performance, with a typical session lasting 60-90 min. 
In addition, the subjects performed a weekly exercise session of 4-5 h (hiking, downhill skiing or snow 
shoe walking). During the exercise sessions, heart rate was controlled with heart rate monitors (Polar, 
S610 I, Polar Electro Europe, Zug, Switzerland) and maintained between 50 and 75% of maximal 
heart rate. 
Behavior modification. Behavior modification focused on lifestyle issues with the aim of modifying 
eating and exercise behavior over the long term. The psychological intervention included self-	
monitoring of calorie intake, weight, praise and stimulus control, but also techniques focusing on 

increasing self-esteem, responsibilities and problem solving strategies. Relaxation techniques and 
breathing therapy were also used. 
Study measurements 
All anthropometric and biochemical measures were carried out at baseline and after eight weeks of 
intervention. Body weight was measured to the nearest 0.1 kg in the morning with the patients wearing 
light clothing and no shoes by using a electronic digital balance (Model 910, Seca, Reinach, 
Switzerland). Height was measured to the nearest 0.5 mm using a wall-mounted stadiometer (Model 
 
222, Seca, Reinach, Switzerland). Body mass index was calculated as body weight in kilograms 
divided by height in meters squared. Body fat was measured using dual-energy X-ray absorption 
(DEXA) (Model 8743, Lunar Prodigy, GE Healthcare, Glattbrugg, Switzerland). Venous blood 
samples were obtained after a 10-hour overnight fast. Following blood sampling, the subjects 
underwent an oral glucose tolerance test and were given 1.75 g glucose/kg body weight (max. 75 g). 
Blood glucose concentration was determined after 1 and 2 hrs in a capillary blood sample. 
Laboratory analysis 
Insulin resistance was estimated by the homeostatic model assessment (HOMA-IR) as follows: 	
HOMA-IR = [fasting insulin (µU/ml) × fasting glucose (mmol/l)/22.5] (14). Serum glucose was 

measured by UV-photometry (Architect Aeroset Glucose, Abbott Clinical Chemistry, Wiesbaden, 
Germany), total cholesterol, triglycerides, HDL- and LDL-cholesterol by enzymatic color reaction 
(Architect Aeroset Cholesterol / Triglycerides / Ultra HDL / LDL, Abbott Clinical Chemistry, 
Wiesbaden, Germany). Serum insulin, fT4, fT3 and TSH concentrations were measured by 
chemiluminescence (Architect System Insulin / Free T4 / Free T3 / TSH, Abbott Diagnostics Division, 
Wiesbaden, Germany), and serum leptin by radioimmunoassay (Human Leptin RIA Kit, Millipore 
(Linco), Molsheim, France). The reference range for TSH was 0.4-6.0 mU/l, and for fT3 and fT4 were 
2.8-6.9 and 0.9-1.8 ng/dl, respectively. A TSH >2.5 and <6  mU/l was classified as high-normal (6). 
Statistical analysis 	
The statistical analysis was done using SPSS for Windows (Version 17.0, Chicago, Illinois, USA) and 

Microsoft Office EXCEL 2007 (Redmond, Washington, USA). All data were controlled for normal 
distribution and non-normally distributed data were log-transformed prior to the analysis. For all 
biochemical parameters, relative differences (in % from baseline) were used to calculate a delta (∆) 
value to take into account the different baseline concentrations. Similarly for the anthropometric 
parameters, relative values were used in order to take into account changes in body composition: % 
weight lost (% baseline weight - % endpoint weight), % fat lost (%  difference from % values) and % 
lean tissue lost (%  difference from % values). To compare BMI values across different ages and by 
 	
gender, BMI-standard deviation scores (SDS) were used. The standard deviation scores were 
calculated using the software Epi Info (version 3.5.1, Centers for Disease Control and Prevention 
(CDC)) based on the CDC recommendations 2000 (15). Differences in BMI-SDS between baseline 
and endpoint were calculated as absolute values. Paired samples t-test was used to analyze differences 
between baseline and after eight weeks of intervention. Univariate Pearson correlations were 
calculated to analyze associations between thyroid function parameters, weight status measures as well 
as components of the metabolic syndrome both for baseline data and for the changes after the 
intervention. Multiple regression models controlling for age, gender and body composition were used 	
to better understand associations between thyroid function and components of the metabolic syndrome. 

The multiple regression models analyzing the changes during the intervention were also done using the 
relative differences for the metabolic parameters (baseline – endpoint). However, the results found 
were very similar to those using the relative differences and are therefore not shown. A p-value of 
<0.05 was considered significant. 
 
Results 
Table 1 shows the anthropometric and metabolic characteristics of the subjects at baseline (n=206) 
and after eight weeks (n=197). The intervention produced rapid loss of weight and fat: mean body 
weight and body fat were reduced by 14.4 kg and 8.7 kg, respectively, corresponding to a loss of 21% 	
of body fat, while only 2.5% of lean tissue was lost. Insulin sensitivity sharply increased, as reflected 

in a >50% decrease in fasting insulin and HOMA. Circulating leptin concentrations decreased 76%. 
The lipid profile improved: there were significant decreases in triglycerides, total and LDL-
cholesterol. There was a significant decrease in TSH and fT3 concentrations during the intervention, 
but no significant change in fT4. At baseline and endpoint, 107 and 87 of the subjects, respectively, 
had a TSH > 2.5 mU/l (high normal), while four and one, respectively, had a TSH > 6.0 mU/l 
(elevated). The children with an elevated TSH were not tested for thyroid antibodies, they were 
observed and not treated. At baseline, three subjects had low fT4 and none had a low fT3; after 8 wks, 
none of the subjects had an elevated fT3 or fT4. Baseline TSH was not significantly correlated with 
 

either baseline fT3 (r=0.108, p=0.122) or fT4 (r=-0.070, p=0.318) but baseline fT3 was correlated to 
baseline fT4 (r=0.138, p=0.045). 
Associations between variables at baseline 
For baseline values, univariate correlations between weight status (body weight, BMI-SDS, fat mass, 
lean body mass and % body fat) and TSH, fT3 and fT4 were calculated. None of the five 
anthropometric indicators correlated with TSH. Body weight (p<0.001, r=-0.253), fat mass (p=0.002, 
r=-0.214) and lean body mass (p=0.004, r=-0.202) significantly negatively correlated with fT3, while 
BMI-SDS (p=0.010, r=0.181) and percentage body fat (p=0.003, r=0.211) positively correlated with 	
fT4. However, in multiple regressions of the weight status indicators on fT3 or fT4 controlling for age 

and gender, none of the above associations remained significant. At baseline, in univariate correlations 
between TSH and variables of lipid and glucose metabolism, there were significant associations of 
TSH with triglycerides (r=0.142, p=0.043), total cholesterol (r=0.184, p=0.008), LDL-cholesterol 
(r=0.173, p=0.013), fasting insulin (r=0.181, p=0.010 (Figure 1), HOMA (r=0.200, p=0.004) but not 
HDL-cholesterol or 2-h glucose during the OGTT. fT3 and fT4 were not significantly correlated with 
any of these variables. Leptin was correlated with TSH (r=0.193, p=0.006) and fT3 (r= -0.214, 
p=0.002), but not fT4. 
Table 2 shows the baseline multiple regression models of TSH as an independent variable on the 
variables of lipid and glucose metabolism, after controlling for each of three obesity measures 	
individually (BMI-SDS, % body fat or lean body mass), along with age and gender. Total cholesterol, 

LDL-cholesterol, fasting insulin and HOMA significantly correlated with TSH even after controlling 
for all three measures of body composition. Triglycerides significantly correlated with TSH 
independent of % body fat, but not after controlling for BMI-SDS or lean body mass. HDL-cholesterol 
and the 2-h glucose during the OGTT did not correlate with TSH. If % body fat was replaced by body 
fat mass, the results of the regression were similar, except for the association with triglycerides, which 
was not significant (p=0.061). Baseline leptin was a significant predictor of baseline TSH after 
adjustment for age, gender and BMI-SDS (β=0.248, p=0.006), % body fat (β=0.330, p=0.001), body 
fat mass (β=0.284, p=0.002), and lean body mass (β=0.261, p=0.001). 
 
Associations between variables during the intervention 
Table 3 shows the univariate correlations during the intervention between loss of body weight and 
change in body composition and ∆TSH, ∆fT3 and ∆fT4. While ∆fT3 was significantly correlated with 
all four indicators of changes in body weight and composition, ∆TSH was not correlated with any of 
the changes in body weight or composition. ∆fT4 correlated only with % change in body weight. In 
univariate correlations between ∆TSH, ∆fT3 or ∆fT4 and the lipid variables, ∆TSH and ∆fT3 were 
predictors of ∆HDL-cholesterol (r=0.197, p=0.006 and r=-0.233, p=0.001) and ∆fT4 was a predictor of 
∆LDL-cholesterol during the intervention (r=-0.157, p=0.028).  	
In multivariate models controlling for age, gender and ∆body weight or body composition, ∆TSH and 

∆fT3 remained predictors of ∆HDL-cholesterol (p<0.01). ∆fT3 and ∆fT4 correlated with ∆leptin 
(r=0.152, p=0.042 and r=-0.147, p=0.049) but were not predictors of ∆fasting insulin or ∆HOMA. 
∆TSH was a not a significant predictor of ∆leptin. Table 4 shows the significant multivariate 
associations between ∆TSH and ∆fasting insulin and ∆HOMA during the intervention, while 
controlling for ∆body weight and ∆composition, as well as age and gender. While ∆TSH significantly 
predicted ∆fasting insulin (r=0.173, p=0.017, see Figure 1) and ∆HOMA (r=0.190, p=0.008), ∆ body 
weight, fat or lean mass did not. The variance in ∆TSH explained 5-6% of the variance in fasting 
insulin and HOMA in all the models.  
 	
Discussion 

Our study is the first to report changes in thyroid function tests and their relation to changes in lipid 
and glucose metabolism during an intensive, well-controlled inpatient intervention to achieve rapid 
weight loss in obese children and adolescents. Previous studies (1, 2, 16) have generally reported on 
smaller groups in less well-controlled, more heterogeneous, long-term outpatient interventions where 
weight loss is much more variable. Strengths of our study include: a) a large group of obese subjects 
who achieved substantial weight loss in a short time; b) a standardized in-patient intervention with 
similar dietary and exercise conditions applied to a relatively homogeneous group; c) measurements in 
 
young subjects not confounded by chronic obesity-related disorders, smoking, alcohol, medications, 
etc.; d) measurement of changes in body composition using DEXA.  Weaknesses of the study are the 
lack of a comparison group of normal weight children and the lack of thyroid antibody data from our 
subjects. However, in adults and children, thyroid autoimmunity does not appear to be increased in 
obesity (3, 17). 
 
Because of varying TSH assays and cut-offs (18), it is difficult to directly compare results, but our data 
generally support previous studies that have reported higher TSH concentrations in obese subjects (3, 	
16, 17, 19). However, despite their severe obesity, TSH concentrations in our subjects were not 

markedly elevated (only 2% had an abnormally high TSH while 52% had a high-normal TSH) and 
there was very little evidence of thyroid hypofunction (only one child had a low fT4).  
 
Although over half of these obese children had high-normal TSH values, baseline TSH or thyroid 
hormones were not correlated with body weight or body composition, after controlling for age and 
gender. Thus, although TSH concentrations tend to be higher in obese children, the elevations in TSH 
show inter-individual variability not explained simply by the amount of excess body weight or fat. 
Rather, our data suggest a close link between leptin and TSH in obese children, independent of body 
weight or fat: at baseline, leptin was a significant predictor of TSH after adjustment for age, gender 	
and body weight and body composition. The lack of correlation between TSH and either fT3 or fT4 

suggests normal feedback of TSH by circulating thyroid hormone is impaired in obese children and 
that high circulating leptin concentrations could play a role. The physiologic relationship between TSH 
and leptin is complex, in that leptin may have stimulatory or inhibitory effects on pituitary TSH 
secretion (11, 20, 21), but at the same time, TSH receptors are present in adipose tissue (22)and TSH 
may directly stimulate production of leptin by adipocytes (12).  
 
 
Because TSH falls with weight loss in some studies (5) it has been suggested that higher TSH in obese 
subjects is simply a consequence of excess body fat. However, weight and/or fat loss does not 
predictably decrease TSH and T3 (1, 16, 19) and in our study, although there was a significant 11% 
decrease in overall mean TSH during the intervention, changes in TSH were not correlated with losses 
of weight, fat or lean tissue during the intervention. Other studies which did not find a decrease in TSH 
with weight loss suggested this could be explained by an inability to accurately quantify fat loss, rather 
than weight loss (1). An advantage of our study was use of DEXA to measure changes in body fat and 
lean tissue. Despite this, we were unable to find a clear relationship between changes in body 	
composition and change in TSH. 

 
It is unclear whether higher TSH in obesity is adaptive, increasing metabolic rate in an attempt to 
reduce further weight gain (5) or indicates subclinical hypothyroidism or resistance, and thereby 
contributes to lipid and/or glucose dysmetabolism. Our data, both at baseline and during the 
intervention, suggest the latter. At baseline, variation in TSH, but not variations in body weight or 
body fat, was a significant predictor of triglycerides, and total- and LDL-cholesterol. Both TSH (but 
not thyroid hormones) and body weight and composition were independent predictors of fasting 
insulin and HOMA, even though only 5-14% of their variation could be explained by the regression 
models (depending on obesity measure used in the model). The fact that baseline fasting insulin and 	
HOMA are not associated with fT3 or fT3 and that baseline leptin is negatively associated with fT3 

and not associated with fT4 further supports this hypothesis. Our data contrast with a previous study in 
obese adolescents, where no association was found between TSH and blood lipids (1). However, they 
are congruent with a larger cross-sectional study in adults which found clear associations between 
TSH concentrations within the normal range and lipid levels (9).  
During the intervention, there was a >50% decrease in mean fasting insulin and HOMA. Strikingly, in 
multivariate regression models these improvements in insulin sensitivity were not predicted by 
changes in body weight, fat or lean mass, or changes in fT3, but rather by ∆TSH during the 
intervention (Table 5). Although only 5-6% of the variance in the change in fasting insulin or HOMA 
 
during the intervention was explained by changes in TSH, this effect was clearly greater than the 
variance in these measures explained by changes in body weight or composition (all <1%, N.S.). 
Cross-sectional studies have reported associations between insulin resistance and TSH (23-25). But 
our prospective data are the first to demonstrate in children and adolescents undergoing weight loss 
that the resulting decrease in TSH, rather than changes in body weight or composition, is the main 
determinant of improvements in fasting insulin and HOMA.  
Although our data are associations and do not prove causality, they suggest that interventions to 
decrease TSH concentrations during weight loss in obese subjects may be beneficial in further 	
increasing insulin sensitivity. However, a recent systematic review concluded the available data do not 

support the use of thyroid hormone therapy in euthyroid obese subjects undergoing caloric deprivation 
(26); the authors suggested randomized placebo-controlled trials with relevant end-points and adequate 
power are needed to prove if there are beneficial effects of thyroid hormone in this setting (26). Our 
findings support this call for larger controlled trials, and suggest that measures of insulin sensitivity 
should be one of the relevant endpoints studied in such studies.  
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Figure 1. During an 8 wk, multidisciplinary inpatient weight loss program in obese children, there 
were significant correlations between; A) baseline concentrations of fasting insulin and TSH 	
(p=0.010); and B) the percentage change (∆) in fasting insulin and ∆TSH during the intervention 

(p=0.017).  
 

 
Table 1: Characteristics of the study population 
 Baseline 8 wk 
N 206 197 
Age  14.1 ± 1.91 14.2 ± 1.9 
Gender ratio (m:f) 119/87 117/80 
Weight (kg) 93.8 ±20.5 79.4 ± 17.23 
BMI-SDS 2.28 ± 0.32 1.86 ± 0.433 
Body fat (kg) 41.6 ± 10.1 32.9 ± 10.03 
Lean tissue (kg) 49.0 ± 10.0 47.8 ± 9.73 
% body fat 46.8 ± 4.7 41.3 ± 6.03 
TSH (mU/l) 2.64 (0.78-8.42)2 2.36 (0.18-6.29)3 
fT3 (ng/dl) 3.8 (2.9-5.7) 3.3 (1.7-4.5)3 
fT4 (ng/dl) 1.2 (0.8-1.6) 1.2 (0.8-1.9) 
Fasting insulin (U/ml) 14.7 (3.5-43.9) 7.1 (3.0-30.4)3 
HOMA 3.0 (0.44-9.68) 1.4 (0.52-5.94)3 
Triglycerides (mg/dl) 103.5 (30.0-354.0) 59.0 (23.0-195.0)3 
Total cholesterol (mg/dl) 172.4 ± 36.7 123.9 ± 25.33 
HDL-cholesterol (mg/dl) 44.7 ± 8.8 43.5 ± 8.73 
LDL-cholesterol (mg/dl) 113.2 ± 31.3 69.6 ± 22.03 
Leptin (µg/l) 29.0 (4.0-89.0) 7.0 (1.0-29.0)3 
1
 mean ± SD (all such values) 
2
 median (range) (all such values) 
3
 significantly different from baseline values (paired samples t-test, p<0.05) 
HOMA was calculated as [fasting insulin (µU/ml) × fasting glucose (mmol/l)/22.5] 
 
 
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Table 2 Multivariate regressions of TSH (independent variable) on blood lipid concentrations and 
measures of insulin resistance (dependent variables) always controlling for one adiposity measure 
(BMI-SDS, % body fat (BF) or lean tissue mass (LTM)) together with age and gender 
 Triglycerides Total cholesterol LDL-cholesterol Fasting insulin HOMA 
 β
*
 p β p β p β p β p 
TSH 
(+ BMI-SDS) 
0.132 0.057 0.179 0.011 0.158 0.025 0.148 0.0271 0.167 0.0131 
TSH 
(+ % BF) 
0.142 0.046 0.179 0.012 0.166 0.022 0.194 0.007 0.215 0.003 
TSH 
(+ LTM) 
0.133 0.0561 0.181 0.011 0.169 0.017 0.189 0.0061 0.210 0.0021 
*standardized coefficient 
1
 the obesity measure was a significant predictor as well (p<0.05) 
 
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Table 3 Univariate correlations between percentage differences (∆) in TSH, free T3 and free T4 and 
percentage changes in weight, fat and lean tissue loss, as well as ∆BMI-SDS after 8 weeks of in-
patient treatment of obese children and adolescents. 
 ∆ TSH abs ∆ T3 abs ∆ T4 abs 
 r* p r p r p 
% weight loss 0.103 0.148 0.088 0.222 -0.189 0.008 
% fat loss -0.071 0.329 0.280 <0.001 -0.081 0.267 
∆ BMI-SDS -0.072 0.321 0.320 <0.001 -0.112 0.121 
% lean tissue loss -0.028 0.706 -0.250 0.001 -0.011 0.876 
*
 pearson correlation coefficients 

 
 
Table 4 In an eight-week, inpatient weight loss intervention in obese children, multiple regression 
analysis with ∆fasting insulin1 or ∆HOMA as the dependent variable and including ∆TSH and either 
percentage loss of total body weight, body fat or lean tissue, with all models controlled for age and 
gender.  
 ∆ Fasting insulin ∆ HOMA 
 β
 2
 p β p 
∆ TSH 0.165 0.023 0.179 0.014 
% weight loss 0.128 0.116 0.132 0.107 
 R2=0.0623 R2=0.062 
     
∆ TSH 0.181 0.014 0.198 0.007 
% fat loss 0.056 0.481 0.040 0.617 
 R2=0.050 R2=0.048 
     
∆ TSH 0.181 0.013 0.198 0.007 
% lean tissue lost -0.118 0.122 -0.103 0.179 
 R2=0.060 R2=0.057 
1
 For all metabolic parameters ∆ values were calculated as relative differences (in % from baseline 
concentrations) 
2
 standardized coefficient 	
3
 R2 values of the entire model including TSH, change in body composition, age and gender 

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